<DOC>
	<DOCNO>NCT01584258</DOCNO>
	<brief_summary>This study international multicentre randomise study organ confine low intermediate risk prostate cancer compose two parallel randomisation scheme base applicability surgery treatment patient . Patients surgery consideration randomise either laparoscopic prostatectomy prostate SBRT . Patients surgery consideration randomise either conventionally fractionated radiation therapy prostate SBRT . Efficacy , toxicity quality life outcome compare across pair randomisation .</brief_summary>
	<brief_title>Prostate Advances Comparative Evidence</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>All following criterion mandatory inclusion : Histological confirmation prostate adenocarcinoma minimum 10 biopsy core take within 18 month randomisation . Gleason score ≤ 3+4 Men age ≥18 Clinical MRI stage T1c T2c , N0X , M0X ( TNM 6th Edition [ 72 ] , See Appendix 1 ) PSA ≤ 20 ng/ml Preenrollment PSA must complete within 60 day randomisation Patients belong one follow risk group accord National Comprehensive Cancer Network ( www.nccn.org ) : Low risk : Clinical stage T1T2a Gleason ≤ 6 PSA &lt; 10 ng/ml , Intermediate risk include one following : Clinical stage T2b orT2c PSA 1020 ng/ml Gleason 3+4 WHO performance status 0 2 Prostate volume ≤ 90 cc measure within 6 month randomisation ( height*width*length *π/6 ) Ability research subject understand willingness sign write informed consent document Exclusion criterion : One follow criterion sufficient exclusion : Clinical stage T3 great Gleason score ≥ 4 + 3 High risk disease define National Comprehensive Cancer Network ( www.nccn.org ) Previous malignancy within last 2 year ( except basal cell carcinoma squamous cell carcinoma skin ) , previous malignancy expect significantly compromise 5 year survival Prior pelvic radiotherapy Prior androgen deprivation therapy ( include LHRH agonist antagonists antiandrogens ) Any prior active treatment prostate cancer . Patients previously active surveillance eligible continue meet eligibility criterion . Life expectancy &lt; 5 year Bilateral hip prosthesis implants/hardware would introduce substantial CT artifacts Medical condition likely make radiotherapy inadvisable eg inflammatory bowel disease , significant urinary symptom Anticoagulation warfarin/ bleed tendency make fiducial placement surgery unsafe opinion clinician ( see section 11 , Treatment ) . Participation another concurrent treatment protocol prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Prostate adenocarcinoma</keyword>
	<keyword>Early stage prostate cancer</keyword>
	<keyword>Organ-confined prostate cancer</keyword>
	<keyword>Low-risk prostate cancer</keyword>
	<keyword>Intermediate-risk prostate cancer</keyword>
</DOC>